Abstract 31P
Background
Cervical cancer is a major public health concern as it is the fourth leading cause of cancer-related fatalities among women. India has the highest incidence of cervical cancer worldwide. Omics diagnostic tools, particularly proteomics, are helpful in tracking the development of the disease as cancer therapy continues to shift towards precision medicine. The primary objective of this study was to explore the global protein expression patterns of cervical cancer in the Indian population for the first time to encourage the application of current diagnostic and treatment modalities.
Methods
We employed MS-based quantitative global (Label-free quantification or LFQ) and targeted proteomics (multiple reaction monitoring or MRM) in bio-banked tissue samples of cervical cancer and healthy tissue (Control=8, Tumor=7; 6 Paired, 2 unpaired). With a very small amount of starting tissue material (10-12 mg) proteomic biomarker profiling was conducted as pilot research. Finally, a complex set of protein candidates belonging to the mRNA splicing and MTORC1 signaling pathway has been confirmed and refined at the peptide level by MRM assay.
Results
We observed proteins belonging to the mRNA processing and maturation via alternative splicing pathway were overexpressed in cervical tumors. Heterogeneous nuclear ribonucleoproteins (hnRNPs), the components of spliceosome complex regulate both constitutive and alternative splicing in tumors. We found at least 5 hnRNPs and few HSP (heat-shock proteins) to be significantly overexpressed in tumors via global proteomics. Validation of candidate hnRNPs (HNRNPA2, HNRNPA1) and Heat-shock proteins (HSPs) were done by targeted proteomics. Furthermore, we developed a comprehensive panel of peptides which can be investigated to check for the effectiveness of tumour development which pave the way towards a better diagnosis.
Conclusions
This foundation study, for the very first time, facilitated the development of a panel of proteomic biomarkers of Cervical cancer in Indian population. We propose that a set of these markers including HNRNPs can be further useful for the development of a complete biomarker panel for cervical cancer diagnosis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Indian Institute of Technology, Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract